Dupilumab-induced ocular surface disease: a primer

Letter Dermatology

Dupilumab-induced ocular surface disease: A systematic review

Tahel Fachler et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Article Ophthalmology

Ocular surface disease associated with dupilumab treatment for atopic diseases

Canan Asli Utine et al.

Summary: Dupilumab, the first FDA approved biologic for atopic dermatitis treatment, may cause conjunctivitis and be associated with Th1-mediated inflammation, suggesting potential adverse effects on ocular health.

OCULAR SURFACE (2021)

Add to Collection

Article Ophthalmology

Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up

Austin Bohner et al.

Summary: This study evaluated a consecutive case series of patients with Dupilumab-associated ocular surface disease (DAOSD), describing common ocular symptoms and signs, proposing a symptom-based grading system, and highlighting the efficacy of treatments like topical corticosteroids. By utilizing a symptom-based grading scale, the study provides insights for nonophthalmic physicians to guide ophthalmology consultations.

CORNEA (2021)

Add to Collection

Review Immunology

Cytokine Regulation and Function in T Cells

Chen Dong

Summary: T lymphocytes play a key role in cellular immunity, with significant heterogeneity in CD4(+) T cells leading to the identification of various subsets with unique roles in immunity and pathology. Understanding cytokine regulation and function has provided innovative treatment options for many human diseases.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 39 (2021)

Add to Collection

Review Critical Care Medicine

Critical Care Management of the Patient With Anaphylaxis: A Concise Definitive Review

Guha Krishnaswamy

Summary: Anaphylaxis is a rapidly progressive life-threatening syndrome that requires familiarity with its diagnosis, evaluation and management. Skilled intervention in ICU settings may be necessary for patients with complicated, severe, or refractory anaphylaxis.

CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Ophthalmology

Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae

Magdalena Z. Popiela et al.

Summary: About 50% of patients with atopic dermatitis (AD) treated with dupilumab developed ocular symptoms, with 67% of them requiring maintenance drops for ongoing ocular inflammation. Periorbital skin changes and conjunctival cicatrisation were noted in association with conjunctivitis. Close liaison with an ophthalmologist is recommended for those patients with a history of severe ocular surface disease or who develop conjunctivitis.

EYE (2021)

Add to Collection

Article Medicine, General & Internal

Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients

Yan Guex-Crosier et al.

Summary: Atopic dermatitis is a chronic inflammatory skin disease often associated with other atopic diseases, and dupilumab is the first biologic approved for its treatment. However, dupilumab therapy may lead to an increased risk of ocular surface diseases in patients with atopic dermatitis. It is recommended that dermatologists closely monitor ocular issues in atopic dermatitis patients undergoing dupilumab therapy, and refer to ophthalmologists when necessary.

SWISS MEDICAL WEEKLY (2021)

Add to Collection

Article Ophthalmology